POXEL SA: Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Fibrosis improvement by 1 stage without worsening

Related Keywords

China ,Boston ,Massachusetts ,United States ,Japan ,Tokyo ,France ,Arthur Rouill ,Dennis Riedl ,Sumitomo Pharma ,Stephen Harrison ,Summit Clinical Research ,Deuterium Stabilizedr Pioglitazone ,Practice Guidelines ,American Association ,Liver Diseases ,European Association ,Euronext Paris ,Ann Intern ,Relations Communication Senior Director ,Vice President ,Investor Relations Communication ,Poxel ,Troxel ,Nnounces ,Publication ,Positive ,Hase ,Results ,Rom ,Cash ,Trial ,Destiny ,Xl065 ,Journal ,Hepatology ,